MARLE GROUP acquired by DENTRESSANGLE
Context
Dentressangle has entered into exclusive negotiations to acquire a majority stake in Marle Group from IK Investment Partners on a preemptive basis, successfully securing the asset outside of a traditional, highly competitive auction process. Marle Group is a premier European leader and a dominant global contract manufacturing organization (CMO) specializing in high-precision orthopedic implants and surgical instruments. The company commands high barriers to entry rooted in its fully vertically integrated manufacturing process (foundry, machining, specialized coating, sterile packaging) and strict international regulatory compliance (FDA, CE mark). Dentressangle’s investment thesis centers on deploying patient, long-term family capital to drive an aggressive international "buy-and-build" strategy (specifically targeting capacity expansion in North America) while diversifying Marle’s capabilities into adjacent high-margin medical device manufacturing niches.
In the past, the company had already been the subject of several LBOs, notably led by The Carlyle Group in 2009 and Ik Partners in 2016. This succession of buyouts highlights the strong attractiveness of the company's business model.
MARLE GROUP, which reported an EBITDA margin of [members only] in 2018, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Marle Group is a world-leading strategic partner and contract development and manufacturing organization (CDMO) dedicated exclusively to the orthopedic and traumatology industry. Headquartered in France, the company provides a complete, vertically integrated value chain—from initial R&D and design assistance to forging, casting, precision machining, specialized coating, and final sterile packaging. Its business model is built on high-precision industrial expertise, supporting global Original Equipment Manufacturers (OEMs) in the production of hip, knee, shoulder, and spine implants, as well as extremity and trauma devices. The organization operates several state-of-the-art production facilities across Europe and the United States, maintaining the most stringent international regulatory certifications (ISO 13485, FDA). Strategically, the firm acts as a mission-critical consolidator in the MedTech supply chain, benefiting from the structural growth in joint replacement surgeries driven by aging global populations and active lifestyles. Its value proposition is centered on "one-stop-shop" efficiency, technical mastery of biocompatible materials, and a commitment to accelerating the time-to-market for innovative surgical solutions.
Ent. Value
€100–200M
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with MARLE GROUP
Other operations with MARLE GROUP
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 12/2023 | MARLE GROUP | NOWAK | FRANCE | Implants & Prosthetics |
| 05/2016 | IK PARTNERS | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 09/2009 | THE CARLYLE GROUP | MARLE GROUP | FRANCE | Implants & Prosthetics |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 02/2020 | TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO | CEVA SANTE ANIMALE | FRANCE | Animal Health |
| 02/2020 | PERRIGO COMPANY | HIGH RIDGE BRANDS (ORAL CARE PORTFOLIO) | UNITED STATES | Generics / Labs |
| 09/2019 | SAGARD | STERIMED | FRANCE | Medical Consumables |
| 08/2019 | PERMIRA | CAMBREX CORPORATION | UNITED STATES | CDMO |
| 07/2019 | BC PARTNERS | Synthon International | NETHERLANDS | Generics / Labs |
| 07/2019 | 3I | IONISOS | FRANCE | CDMO |
| 07/2019 | PERMIRA | QUOTIENT SCIENCES | UNITED KINGDOM | CDMO |
| 05/2019 | ARDIAN | SINTETICA | SWITZERLAND | Pharma & Biotech |
| 04/2019 | EURAZEO | D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) | NETHERLANDS | Medical Devices |
| 04/2019 | ICG / MERIEUX EQUITY PARTNERS | DOC GENERICI | ITALY | Generics / Labs |
Other operations with DENTRESSANGLE
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2026 | DENTRESSANGLE | TEKLYNX | FRANCE | Supply Chain & Ops |
| 09/2024 | DENTRESSANGLE | EDL | FRANCE | Healthcare |
| 12/2018 | DENTRESSANGLE | BIG MAMMA | FRANCE | Restaurants / Chains |
| 08/2018 | DENTRESSANGLE | ACTEON | FRANCE | Medical Devices |
| 11/2011 | DENTRESSANGLE | CHEMICA | FRANCE | Plastics |
REFERENCES
Revenue range: €100–200M
EBITDA range: €25–50M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of MARLE GROUP by DENTRESSANGLE are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: marle group
Acquirer: dentressangle